582 related articles for article (PubMed ID: 16294265)
21. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase.
Glantschnig H; Fisher JE; Wesolowski G; Rodan GA; Reszka AA
Cell Death Differ; 2003 Oct; 10(10):1165-77. PubMed ID: 14502240
[TBL] [Abstract][Full Text] [Related]
22. Homocysteine enhances bone resorption by stimulation of osteoclast formation and activity through increased intracellular ROS generation.
Koh JM; Lee YS; Kim YS; Kim DJ; Kim HH; Park JY; Lee KU; Kim GS
J Bone Miner Res; 2006 Jul; 21(7):1003-11. PubMed ID: 16813521
[TBL] [Abstract][Full Text] [Related]
23. Autocrine and paracrine nitric oxide regulate attachment of human osteoclasts.
Yaroslavskiy BB; Li Y; Ferguson DJ; Kalla SE; Oakley JI; Blair HC
J Cell Biochem; 2004 Apr; 91(5):962-72. PubMed ID: 15034931
[TBL] [Abstract][Full Text] [Related]
24. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
25. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
[TBL] [Abstract][Full Text] [Related]
26. Isolation of human osteoclasts formed in vitro: hormonal effects on the bone-resorbing activity of human osteoclasts.
Kudo O; Sabokbar A; Pocock A; Itonaga I; Athanasou NA
Calcif Tissue Int; 2002 Dec; 71(6):539-46. PubMed ID: 12232680
[TBL] [Abstract][Full Text] [Related]
27. Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model.
Rissanen JP; Suominen MI; Peng Z; Halleen JM
Calcif Tissue Int; 2008 Feb; 82(2):108-15. PubMed ID: 18084692
[TBL] [Abstract][Full Text] [Related]
28. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
29. Disruption of claudin-18 diminishes ovariectomy-induced bone loss in mice.
Kim HY; Alarcon C; Pourteymour S; Wergedal JE; Mohan S
Am J Physiol Endocrinol Metab; 2013 Mar; 304(5):E531-7. PubMed ID: 23299504
[TBL] [Abstract][Full Text] [Related]
30. Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow.
Shibata T; Shira-Ishi A; Sato T; Masaki T; Masuda A; Hishiya A; Ishikura N; Higashi S; Uchida Y; Saito MO; Ito M; Ogata E; Watanabe K; Ikeda K
J Bone Miner Res; 2002 Apr; 17(4):622-9. PubMed ID: 11918219
[TBL] [Abstract][Full Text] [Related]
31. Gymnasterkoreayne F inhibits osteoclast formation by suppressing NFATc1 and DC-STAMP expression.
Kim HJ; Hong J; Jung JW; Kim TH; Kim JA; Kim YH; Kim SY
Int Immunopharmacol; 2010 Nov; 10(11):1440-7. PubMed ID: 20831919
[TBL] [Abstract][Full Text] [Related]
32. A bio-assay for effectors of osteoclast differentiation in serum from patients with bone disease.
Dugard MN; Sharp CA; Evans SF; Williams JH; Davie MW; Marshall MJ
Clin Chim Acta; 2005 Jun; 356(1-2):154-63. PubMed ID: 15936312
[TBL] [Abstract][Full Text] [Related]
33. Absence of Dap12 and the αvβ3 integrin causes severe osteopetrosis.
Zou W; Teitelbaum SL
J Cell Biol; 2015 Jan; 208(1):125-36. PubMed ID: 25547154
[TBL] [Abstract][Full Text] [Related]
34. Neohesperidin suppresses osteoclast differentiation, bone resorption and ovariectomised-induced osteoporosis in mice.
Tan Z; Cheng J; Liu Q; Zhou L; Kenny J; Wang T; Lin X; Yuan J; Quinn JMW; Tickner J; Hong G; Qin A; Zhao J; Xu J
Mol Cell Endocrinol; 2017 Jan; 439():369-378. PubMed ID: 27664516
[TBL] [Abstract][Full Text] [Related]
35. Ncf1 affects osteoclast formation but is not critical for postmenopausal bone loss.
Stubelius A; Andersson A; Holmdahl R; Ohlsson C; Islander U; Carlsten H
BMC Musculoskelet Disord; 2016 Nov; 17(1):464. PubMed ID: 27829407
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis.
Lee SK; Kalinowski JF; Jastrzebski SL; Puddington L; Lorenzo JA
Endocrinology; 2003 Aug; 144(8):3524-31. PubMed ID: 12865334
[TBL] [Abstract][Full Text] [Related]
37. Bach1 regulates osteoclastogenesis in a mouse model via both heme oxygenase 1-dependent and heme oxygenase 1-independent pathways.
Hama M; Kirino Y; Takeno M; Takase K; Miyazaki T; Yoshimi R; Ueda A; Itoh-Nakadai A; Muto A; Igarashi K; Ishigatsubo Y
Arthritis Rheum; 2012 May; 64(5):1518-28. PubMed ID: 22127667
[TBL] [Abstract][Full Text] [Related]
38. Quercetin suppresses bone resorption by inhibiting the differentiation and activation of osteoclasts.
Woo JT; Nakagawa H; Notoya M; Yonezawa T; Udagawa N; Lee IS; Ohnishi M; Hagiwara H; Nagai K
Biol Pharm Bull; 2004 Apr; 27(4):504-9. PubMed ID: 15056855
[TBL] [Abstract][Full Text] [Related]
39. A Glanzmann's mutation in beta 3 integrin specifically impairs osteoclast function.
Feng X; Novack DV; Faccio R; Ory DS; Aya K; Boyer MI; McHugh KP; Ross FP; Teitelbaum SL
J Clin Invest; 2001 May; 107(9):1137-44. PubMed ID: 11342577
[TBL] [Abstract][Full Text] [Related]
40. Cloning and characterization of osteoclast precursors from the RAW264.7 cell line.
Cuetara BL; Crotti TN; O'Donoghue AJ; McHugh KP
In Vitro Cell Dev Biol Anim; 2006; 42(7):182-8. PubMed ID: 16948499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
